Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
about
Apoptosis - associated genes and their role in predicting responses to neoadjuvant breast cancer treatment.Which patients pursue fertility preservation treatments? A multicenter analysis of the predictors of fertility preservation in women with breast cancerRandomized adjuvant trials in oncology: a necessity or time-consuming luxury?Shrink pattern of breast cancer after neoadjuvant chemotherapy and its correlation with clinical pathological factors.Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging.Diagnostic performance of magnetic resonance imaging for assessing tumor response in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy is associated with molecular biomarker profile.Controversies in breast cancer: adjuvant and neoadjuvant therapy.ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosisGuidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women's Cancer Initiative - Tata Memorial Hospital (WCI-TMH) ConferenceAxillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literaturePrimary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.Imaging and dosimetry of 99mTc EC annexin V: preliminary clinical study targeting apoptosis in breast tumors.The role of oncoplastic breast conserving treatment for locally advanced breast tumors. A matching case-control studyBreast-conserving surgery in locally advanced breast cancer submitted to neoadjuvant chemotherapy. Safety and effectiveness based on ipsilateral breast tumor recurrence and long-term follow-up.Neoadjuvant treatments for triple-negative breast cancer (TNBC).Management of infection following reconstruction in bone tumors.Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma.Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy.Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery.High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy.The Inner and Outer Qualities of Extracellular Vesicles for Translational Purposes in Breast Cancer.A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.Surgical Considerations After Neoadjuvant Chemotherapy: Breast Conservation Therapy.CDK9 Expression Shows Role as a Potential Prognostic Biomarker in Breast Cancer Patients Who Fail to Achieve Pathologic Complete Response after Neoadjuvant Chemotherapy
P2860
Q34114155-9E7CA8FB-C6AA-497E-B286-4D6664339650Q34314894-DE650EAB-EEFF-41D4-B7C8-32E2AC9046EBQ34423520-D123F6E5-7236-4AF4-8188-C3EED8CB2EEAQ34863131-6051DDF2-D6BC-4A9A-82B1-6620E85A6074Q35560975-F13E75F5-8459-4388-A668-9EC624233386Q35928203-392965A8-627D-4B41-B9B2-6BB6CC7133C1Q36163952-BD4B956E-F8FC-4FD7-9AE6-BA8AF9E70BC9Q36175526-473A2D5F-9C5A-4A5A-9414-3C565074DE8EQ36228114-73FAEEBB-6913-4A99-84B3-48A80A7FAD67Q36420776-0AEB44CD-49F0-4C88-A37A-95340F3EED68Q36615222-B2AE4D4B-176C-4F3B-A0D9-DEA90EB14379Q36924133-D352863D-8F47-42DA-A6C8-0EDBDA9C1017Q37171652-046BFAC0-69C7-4979-8876-F3B5777CB956Q37697506-4FF97BD1-00D5-4CA6-A728-EF3697B16303Q38046580-A9EDE83D-7591-44FB-9353-C474859B3BB6Q38632884-DA55C515-02E2-45CC-A72C-D798497B8695Q46525479-3778C7BF-7855-44DC-9C51-1AA1FD67BB81Q48222174-355F4029-C51D-472F-8BC5-C392A42347C1Q50534660-4B3D59A0-6E5D-4CA8-B7B8-D73A6E5DE053Q50916771-BEFAD953-AD0D-4C65-A09F-EBFA639746C6Q51813446-2E618767-A9C3-4EB3-94DA-5F14B8BC9656Q52597634-753699BB-094E-4FC5-993A-CD5236ADA44EQ53402025-4A648A49-9AF5-4EBD-A8B5-20E252EAF594Q53471110-C83E7823-D3AD-40D4-AA25-5F94B5AD1462Q58567485-DB62D698-6477-42A7-B8A4-6C95FE0DFACA
P2860
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks.
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@ast
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@en
type
label
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@ast
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@en
prefLabel
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@ast
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@en
P2093
P356
P1433
P1476
Neoadjuvant chemotherapy for b ...... rations of benefits and risks.
@en
P2093
Aysegul A Sahin
Gabriel N Hortobagyi
Gary J Whitman
Kelly K Hunt
Thomas A Buchholz
P304
P356
10.1002/CNCR.11603
P407
P577
2003-09-01T00:00:00Z